Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

ESMO Open - Tập 4 - Trang e000596 - 2019
Amanda Katherina Herbrand1, Andreas Michael Schmitt1, Matthias Briel2,3, Stefan Diem4,5, Hannah Ewald2,6, Anouk Hoogkamer1, Markus Joerger5, Kimberly Alba Mc Cord2, Urban Novak7, Sirintip Sricharoenchai2, Lars G Hemkens2, Benjamin Kasenda1,2,8
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
2Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
3Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
4Department of Oncology and Hematology, Kantonales Spital Grabs, Grabs, Switzerland
5Department of Oncology and Hematology, Kantonsspital St. Gallen, Sankt Gallen, Switzerland
6University Medical Library, University of Basel, Basel, Switzerland
7Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
8Department of Hematology/Oncology and Palliative Care, Klinikum Stuttgart Katharinenhospital, Stuttgart, Germany

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

ESMO Open

Tập 4

e000596

Thông tin tác giả